An observational study in Melanoma of Skin, sponsored by Ente Ospedaliero Ospedali Galliera. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Ente Ospedaliero Ospedali Galliera · Observational
The primary objective of the study is to analyse a local cohort of patients aged 18-39 years with melanoma diagnosis in order to determine the prevalence of the disease in this age group.
Secondary objectives are the following:
3,370 studies on the registry are indexed under Melanoma; 578 are open to participants now.
This study's planned enrollment of 25 is below the median of 187 across 488 observational studies indexed under Melanoma.
Browse Melanoma studies →Ente Ospedaliero Ospedali Galliera is the lead sponsor of 19 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Since there are no epidemiological data about the prevalence of melanoma in subjects aged 18-39 years, there are very few data available on risk factors in this age group and the impact of the disease.
The present study, therefore, will enroll about 25 patients who will attend the Dermatology Unit and who have a histological diagnosis of cutaneous melanoma in a period of 24 months of observation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with melanoma diagnosis aged between 18 and 39 years.
Melanoma prevalence
Estimated prevalence of melanoma in a cohort group of patients aged 18 - 39 years
Time frame: 3 years
Risk factor
Identification of risk factors associated with melanoma in young people.
Time frame: 3 years
Melanoma phenotype
Description of the main phenotypic of melanoma in this age group.
Time frame: 3 years
Histopathological feature
Evaluation of the likely association between clinical and histopathological features of melanoma in young people.
Time frame: 3 years
Mutational status
Identification of the presence of B-RAF mutations
Time frame: 3 years
Dermoscopy of melanoma
Description of the main dermoscopic characteristics of melanoma in this age group.
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 20 months after the start.
Of 177 non-industry observational studies under Melanoma, half reached primary completion within 178 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 320. This study's planned 20 months is below that.
Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 223.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ente Ospedaliero Ospedali Galliera